Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The trial investigators wanted to see if the drug was an effective psoriasis treatment ... Scalp-Investigator Global Assessment (S-IGA) and Body-IGA (B-IGA) scores. Both are five-point scales ...

may improve treatment outcomes by increasing adherence. Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body ...

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

The IGA is a five-point scale with a severity ... A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...